Table 3.
Baseline Patient Characteristics of the endTB Observational Study Cohort Enrolled 1 April 2015–30 June 2018a
| Patient Characteristics | Total, |
|---|---|
| n (%) | |
| Median age at registration (interquartile range), years | 36 (27–46) |
| Age (range), years | (9–88) |
| Male | 1480 (64.5) |
| Comorbidities | |
| Diabetes mellitus (N = 2277) | 343 (15.3) |
| Living with human immunodeficiency virus (N = 2296) | 316 (13.8) |
| Hepatitis B surface antigen positivity (N = 2269) | 104 (4.6) |
| Hepatitis C antibody positivity (N = 2274) | 259 (11.4) |
| At least 1 other comorbidityb | 229 (10.0) |
| Body mass index < 18 kg/m2 (N = 1899) | 592 (31.2) |
| Disease characteristics | |
| Past TB treatments (N = 2294) | |
| No prior TB treatment | 306 (13.3) |
| Received prior TB treatment only with first-line TB drugs | 351 (15.3) |
| Received prior TB treatment with second-line TB drugs | 1637 (71.4) |
| Extrapulmonary disease only | 18 (0.8) |
| Radiographic findings | |
| Bilateral disease (N = 2026) | 1355 (66.9) |
| Cavitary disease (N = 1968) | 1198 (60.9) |
| Smear 2 + and cavitary disease (N = 1894) | 345 (18.2) |
| Resistance profile | |
| RR/MDR-TB without injectable or fluoroquinolone resistance | 464 (20.2) |
| RR/MDR-TB without second-line drug susceptibility results | 274 (11.9) |
| RR/MDR-TB with injectable resistance | 292 (12.7) |
| RR/MDR-TB with fluoroquinolone resistance | 548 (23.9) |
| XDR-TB | 683 (29.7) |
| No results for RR/MDR | 35 (1.5) |
Abbreviations: MDR, multidrug-resistant; RR, rifampicin-resistant, TB resistant to rifampicin and isoniazid; TB, tuberculosis; XDR, extensively drug-resistant, TB resistant to both a fluoroquinolone and at least 1 injectable drug (capreomycin, amikacin or kanamycin).
N = 2296 unless otherwise stated.
Patients with TB and at least one of the above listed co-morbidities; diabetes mellitus, HIV, hepatitis B or hepatitis C.